Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunization

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Biron, Kaan E ^a,b,c   Dickstein, Dara L ^d   Gopaul, Rayshad ^a,b,c   Fenninger, Franz ^a,b,c   Jefferies, Wilfred A ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; C57BL MOUSE; DISEASE MODEL; FEMALE; IMMUNIZATION; IMMUNOLOGY; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TIGHT JUNCTION; TRANSGENIC MOUSE; VASCULARIZATION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; TIGHT JUNCTIONS;

MLCS; MLOWN;

EID: 84874619562     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01354     Document Type: Article

References (40)

1. Castellani, R. J., Rolston, R. K. & Smith, M. A. Alzheimer disease. Dis Mon 56, 484-546 (2010)
2. Hardy, J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 3, 71-73 (2006)
3. Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nature reviews. Neuroscience 12, 723-738 (2011)
4. Paul, J., Strickland, S. and Melchor, J. P. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 204, 1999-2008 (2007) (Pubitemid 47236333)
5. Biron, K. E., Dickstein, D. L., Gopaul, R. & Jefferies, W. A. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS ONE 6, e23789 (2011)
6. Neugroschl, J. & Sano, M. Current treatment and recent clinical research in Alzheimer's disease. Mt Sinai J Med 77, 3-16 (2010)
7. Citron, M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9, 387-398 (2010)
8. Morgan, D. Immunotherapy for Alzheimer's disease. J Intern Med 269, 54-63 (2011)
9. Golde, T. E., Das, P. & Levites, Y. Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol Disord Drug Targets 8, 31-49 (2009)
10. Dickstein, D. L. et al. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J 20, 426-433 (2006) (Pubitemid 44933319)
11. Wilcock, D. M. & Colton, C. A. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15, 555-569 (2008)
12. Vasilevko, V. et al. Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Annals of the New York Academy of Sciences 1207, 58-70 (2010)
13. Masliah, E. et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131 (2005) (Pubitemid 40082949)
14. Delrieu, J., Ousset, P. J., Caillaud, C. & Vellas, B. 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 120 Suppl 1, 186-193 (2012)
15. Boche, D. et al. Consequence ofAOE#immunization on the vasculature of human Alzheimer's disease brain. Brain 131, 3299-3310 (2008)
16. Menendez-Gonzalez, M., Perez-Pinera, P., Martinez-Rivera, M., Muniz, A. L. & Vega, J. A. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. Current pharmaceutical design 17, 508-520 (2011)
17. Ujiie, M., Dickstein, D., Carlow, D. & Jefferies, W. A. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463-470 (2003) (Pubitemid 39004272)
18. Farrall, A. J. & Wardlaw, J. M. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 30, 337-352 (2009)
19. Holley, J. E., Newcombe, J., Whatmore, J. L. & Gutowski, N. J. Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci Lett 470, 65-70 (2010)
20. Barresi, V., Cerasoli, S., Vitarelli, E. & Tuccari, G. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol 114, 147-156 (2007) (Pubitemid 47103525)
21. Streit, W. J., Mrak, R. E. & Griffin, W. S. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 1, 14 (2004)
22. Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15, 349-357 (2012)
23. Pogue, A. I. & Lukiw, W. J. Angiogenic signaling in Alzheimer's disease. Neuroreport 15, 1507-1510 (2004) (Pubitemid 38925253)
24. Cameron, D. J. et al. Alzheimer's-Related Peptide Amyloid-beta Plays a Conserved Role in Angiogenesis. PLoS One 7, e39598 (2012)
25. Nicoll, J. A. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9, 448-452 (2003)
26. Harrison, R. S., Sharpe, P. C., Singh, Y. & Fairlie, D. P. Amyloid peptides and proteins in review. Rev Physiol Biochem Pharmacol 159, 1-77 (2007)
27. Suzuki, N. et al. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 145, 452-460 (1994) (Pubitemid 24245845)
28. Prelli, F., Castano, E., Glenner, G. G. & Frangione, B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 51, 648-651 (1988)
29. Patton, R. L. et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169, 1048-1063 (2006) (Pubitemid 44411966)
30. Nicoll, J. A. et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65, 1040-1048 (2006)
31. Boche, D. et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131, 3299-3310 (2008)
32. Wilcock, D. M. et al. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci 29, 7957-7965 (2009)
33. Racke, M. M. et al. Exacerbation of cerebral amyloid angiopathy- associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25, 629-636 (2005)
34. Park, L. et al. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci 25, 1769-1777 (2005) (Pubitemid 40279282)
35. Weller, R. O., Preston, S. D., Subash, M. & Carare, R. O. Cerebral amyloid angiopathy in the aetiology and immunotherapy ofAlzheimer disease. Alzheimers Res Ther 1, 6 (2009)
36. Herzig, M. C., Van Nostrand, W. E. & Jucker, M. Mechanism of cerebral betaamyloid angiopathy: murine and cellular models. Brain Pathol 16, 40-54 (2006)
37. Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506 (2012)
38. Qu, L. & Tang, X. Bexarotene: a promising anticancer agent. Cancer Chemother Pharmacol 65, 201-205 (2010)
39. Yen, W. C., Prudente, R. Y., Corpuz, M. R., Negro-Vilar, A. & Lamph, W. W. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. British journal of cancer 94, 654-660 (2006) (Pubitemid 43361896)
40. Hsiao, K. et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996). (Pubitemid 26332733)